145 related articles for article (PubMed ID: 12070827)
21. The continuous changes in the aetiology and epidemiology of invasive candidiasis: from familiar Candida albicans to multiresistant Candida auris.
Quindós G; Marcos-Arias C; San-Millán R; Mateo E; Eraso E
Int Microbiol; 2018 Sep; 21(3):107-119. PubMed ID: 30810955
[TBL] [Abstract][Full Text] [Related]
22. Antifungal susceptibilities of Candida species isolated from urine culture.
Toka Özer T; Durmaz S; Yula E
J Infect Chemother; 2016 Sep; 22(9):629-32. PubMed ID: 27452427
[TBL] [Abstract][Full Text] [Related]
23. Resistance of Candida species to antifungal agents used in the treatment of onychomycosis: a review of current problems.
Evans EG
Br J Dermatol; 1999 Nov; 141 Suppl 56():33-5. PubMed ID: 10730912
[TBL] [Abstract][Full Text] [Related]
24. [The changing pattern of Candida infections: different species and increased resistance].
Kullberg BJ; Voss A
Ned Tijdschr Geneeskd; 1996 Jan; 140(3):148-51. PubMed ID: 8618635
[TBL] [Abstract][Full Text] [Related]
25. Candida parapsilosis fungemia in cancer patients--incidence, risk factors and outcome.
Krcméry V; Spánik S; Grausová S; Trupl J; Krupová I; Roidová A; Sálek T; Sufliarsky J; Mardiak J
Neoplasma; 1998; 45(5):336-42. PubMed ID: 9921924
[TBL] [Abstract][Full Text] [Related]
26. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance.
Nguyen MH; Peacock JE; Morris AJ; Tanner DC; Nguyen ML; Snydman DR; Wagener MM; Rinaldi MG; Yu VL
Am J Med; 1996 Jun; 100(6):617-23. PubMed ID: 8678081
[TBL] [Abstract][Full Text] [Related]
27. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance.
Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2006 Mar; 44(3):760-3. PubMed ID: 16517851
[TBL] [Abstract][Full Text] [Related]
28. Invasive Candida infections: the changing epidemiology.
Marr KA
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 13):9-14. PubMed ID: 15682589
[TBL] [Abstract][Full Text] [Related]
29. Clinical applicability of antifungal susceptibility testing on non-Candida albicans species in hospitalized patients.
Wong-Beringera A; Hindler J; Brankovic L; Muehlbauer L; Steele-Moore L
Diagn Microbiol Infect Dis; 2001 Jan; 39(1):25-31. PubMed ID: 11173188
[TBL] [Abstract][Full Text] [Related]
30. [Isolation rate and susceptibilities of candida species from blood, vascular catheter, urine and stool].
Tashiro M; Murakami H; Yoshizawa S; Tateda K; Yamaguchi K
Kansenshogaku Zasshi; 2012 Mar; 86(2 Suppl 4):15-20. PubMed ID: 23115940
[TBL] [Abstract][Full Text] [Related]
31. Antifungal resistance: the clinical front.
Perfect JR
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 13):15-22. PubMed ID: 15682590
[TBL] [Abstract][Full Text] [Related]
32. Breakthrough Candida dubliniensis fungemia in an acute myeloid leukemia patient during voriconazole therapy successfully treated with caspofungin.
Fanci R
J Chemother; 2009 Feb; 21(1):105-7. PubMed ID: 19297283
[No Abstract] [Full Text] [Related]
33. Hematogenous infections due to Candida parapsilosis: changing trends in fungemic patients at a comprehensive cancer center during the last four decades.
Safdar A; Perlin DS; Armstrong D
Diagn Microbiol Infect Dis; 2002 Sep; 44(1):11-6. PubMed ID: 12376025
[TBL] [Abstract][Full Text] [Related]
34. Impact of antifungal prescription on relative distribution and susceptibility of Candida spp. - Trends over 10 years.
Bailly S; Maubon D; Fournier P; Pelloux H; Schwebel C; Chapuis C; Foroni L; Cornet M; Timsit JF
J Infect; 2016 Jan; 72(1):103-11. PubMed ID: 26518058
[TBL] [Abstract][Full Text] [Related]
35. Occurrence of oral Candida colonization and its risk factors among patients with malignancies in China.
Sun H; Chen Y; Zou X; Li H; Yin X; Qin H; Liu R; Yu C; Li Q; Yu K; Han X; Zou J; Ge C; Han L
Clin Oral Investig; 2016 Apr; 20(3):459-67. PubMed ID: 26220512
[TBL] [Abstract][Full Text] [Related]
36. Changes in the distribution of colonising and infecting Candida spp. isolates, antifungal drug consumption and susceptibility in a French intensive care unit: A 10-year study.
Sasso M; Roger C; Sasso M; Poujol H; Barbar S; Lefrant JY; Lachaud L
Mycoses; 2017 Dec; 60(12):770-780. PubMed ID: 28758337
[TBL] [Abstract][Full Text] [Related]
37. Epidemiology, antifungal susceptibilities, and risk factors for invasive candidiasis from 2011 to 2013 in a teaching hospital in southwest China.
Pu S; Niu S; Zhang C; Xu X; Qin M; Huang S; Zhang L
J Microbiol Immunol Infect; 2017 Feb; 50(1):97-103. PubMed ID: 25769664
[TBL] [Abstract][Full Text] [Related]
38. Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management.
Chen SC; Marriott D; Playford EG; Nguyen Q; Ellis D; Meyer W; Sorrell TC; Slavin M;
Clin Microbiol Infect; 2009 Jul; 15(7):662-9. PubMed ID: 19614718
[TBL] [Abstract][Full Text] [Related]
39. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
Horn DL; Neofytos D; Anaissie EJ; Fishman JA; Steinbach WJ; Olyaei AJ; Marr KA; Pfaller MA; Chang CH; Webster KM
Clin Infect Dis; 2009 Jun; 48(12):1695-703. PubMed ID: 19441981
[TBL] [Abstract][Full Text] [Related]
40. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
Safdar A; van Rhee F; Henslee-Downey JP; Singhal S; Mehta J
Bone Marrow Transplant; 2001 Nov; 28(9):873-8. PubMed ID: 11781648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
